http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Kyeong Seok,Yang, Hun Yong,Song, Hosup,Kang, Ye Rim,Kwon, JiHoon,An, JiHye,Son, Ji Yeon,Kwack, Seung Jun,Kim, Young-Mi,Bae, Ok-Nam,Ahn, Mee-Young,Lee, Jaewon,Yoon, Sungpil,Lee, Byung μ,Kim, Hyung TAYLOR & FRANCIS 2017 Journal of Toxicology and Environmental Health Vol.80 No.9
<P>Acute kidney injury (AKI) is associated with increased mortality rate in patients but clinically available biomarkers for disease detection are currently not available. Recently, a new biomarker, selenium-binding protein 1 (SBP1), was identified for detection of nephrotoxicity using proteomic analysis. The aim of this study was to assess the sensitivity of urinary SBP1 levels as an early detection of AKI using animal models such as cisplatin or ischemia/reperfusion (I/R). Sprague-Dawley rats were injected with cisplatin (6 mg/kg, once i.p.) and sacrificed at 1, 3, or 5 days after treatment. Ischemia was achieved by bilaterally occluding both kidneys with a microvascular clamp for 45 min and verified visually by a change in tissue color. After post-reperfusion, urine samples were collected at 9, 24, and 48 hr intervals. Urinary excretion of protein-based biomarkers was measured by Western blot analysis. In cisplatin-treated rats, mild histopathologic alterations were noted at day 1 which became severe at day 3. Blood urea nitrogen (BUN) and serum creatinine (SCr) levels were significantly increased at day 3. Levels of urinary excretion of SBP1, neutrophil gelatinase-associated lipocalin (NGAL), and a tissue inhibitor of metalloproteinase-1 (TIMP-1) were markedly elevated at day 3 and 5 following drug treatment. In the vehicle-treated I/R group, serum levels of BUN and SCr and AST activity were significantly increased compared to sham. Urinary excretion of SBP1 and NGAL rose markedly following I/R. The urinary levels of SBP1, NGAL, TIMP-1, and KIM-1 proteins excreted by AKI patients and normal subjects were compared. Among these proteins, a marked rise in SBP1 was observed in urine of patients with AKI compared to normal subjects. Based upon receiver-operator curves (ROC), SBP1 displayed a higher area under the curve (AUC) scores than levels of SCr, BUN, total protein, and glucose. In particular, SBP1 protein was readily detected in small amounts of urine without purification. Data thus indicate that urinary excretion of SBP1 may be useful as a reliable biomarker for early diagnosis of AKI in patients.</P>
Choi, Young Deuk,Ham, Won Sik,Kim, Won Tae,Cho, Kang Su,Lee, Joo Hyoung,Cho, Soung Yong,Seo, Ju Wan,Jin, Ok Hyun Mary Ann Liebert 2009 Journal of endourology Vol.23 No.6
<P>PURPOSE: To evaluate the efficacy and safety of single-session OK-432 sclerotherapy for the treatment of renal cysts. MATERIALS AND METHODS: From October 2005 to November 2006, 48 patients (61 simple renal cysts) were included in the study. Indications were determined as flank discomfort (n = 37) or patient reassurance due to increasing size (n = 11). The simple renal cysts were aspirated under ultrasonography (US), at which point OK-432 was injected into the cyst. Follow-up was performed with US or computed tomography scan every 3 months until 1 year. Complete regression of the renal cyst or more than 70% reduction in size with no symptoms indicated a successful treatment. RESULTS: Among 61 renal cysts of 48 patients, the overall success rate was 98.4%. Complete regression occurred in 46 cysts (75.4%), and more than 90% reduction in size occurred in 6 cysts (9.8%). A size reduction of 80% to 90% and 70% to 80% occurred in five (8.2%) and three cysts (4.9%), respectively. A size reduction less than 70% occurred in only one cyst (1.6%). The success of cyst regression was correlated with cyst volume. Clinical symptoms resolved in 100% of patients with symptomatic cysts, and there was no enlargement of the aspirated cysts at the 1-year follow-up. After the procedure, there were only some minor complications, such as mild fever, flank pain, and leukocytosis, which subsided with the conservative treatment. CONCLUSIONS: Percutaneous OK-432 sclerotherapy is simple, safe, and effective, and it can be an alternative first-line therapy for simple renal cysts.</P>
Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer
오형주,( Ha Young Park ),( Tae Ok Kim1 ),( Chul Kyu Park ),( Hong Jun Shin ),( Hee Jung Ban ),( In Jae Oh ),( Yong Soo Kwon ),( Yu Il Kim ),( Sung Chul Lim ),( Young Chul Kim ),( Soo Hyun Kim ),( Myung G 대한결핵 및 호흡기학회 2015 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.120 No.-
Background: Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We aimed this study for evaluating the usefulness of automated proGRP measurement for diagnosis and treatment monitoring in patients with SCLC. Methods: From January 2011 to December 2013, plasma samples were prospectively collected from 452 [213 non-small cell lung cancer (NSCLC), 104 SCLC, 135 other diseases] patients visited for tissue diagnosis and tested by two-step automated immunoassay using the ARCHITECT proGRP assay kit (Abbott Diagnostics, USA). The cutoff level of proGRP was set at 63 pg/mL. Results: The mean proGRP was higher in SCLC (1823.0 ± 2684.0 pg/mL) than in NSCLC (61.0 ± 341.7 pg/mL) and other diseases (51.5 ± 222.6 pg/mL, p<0.001). The sensitivity of proGRP was 85.7% (90/105) in SCLC and 11.8% (25/212) in NSCLC. The specificity was 90.2%, positive predictive value was 72.5%, and negative predictive value was 95.4% in SCLC. The mean proGRP was higher in extensive disease (2158.1 ± 2980.6 pg/mL) than in limited disease (901.4 ± 1216.0 pg/mL, p=0.033). Among the 39 patients with SCLC could be followed, the mean proGRP levels of 23 responders were significantly decreased after chemotherapy (from 1651.5 ± 1386.4 pg/mL to 290.0 ± 524.8 pg/mL, p<0.001), whereas those of the 16 non-responders were not. (from 572.5 ± 790.3 pg/mL to 494.4 ± 610.9 pg/mL, p=0.583). Conclusion: Plasma proGRP could be a useful biomarker of SCLC for diagnosis and treatment monitoring. And the initial level may represent the tumor extent of SCLC.
Kim, Yong Kyun,Kim, Su-Hyun,Kim, Hyung Wook,Kim, Young Ok,Jin, Dong Chan,Song, Ho Chul,Choi, Euy Jin,Kim, Yong-Lim,Kim, Yon-Su,Kang, Shin-Wook,Kim, Nam-Ho,Yang, Chul Woo SAGE Publications 2014 Peritoneal dialysis international Vol.34 No.4
<B>Background</B><P> Previous studies have demonstrated that increased body mass index (BMI) is associated with decreased mortality in hemodialysis (HD) patients. However, the association between BMI and survival has not been well established in patients undergoing peritoneal dialysis (PD). The aim of the study was to determine the association between BMI and mortality in the PD population using the Clinical Research Center (CRC) registry for end-stage renal disease (ESRD) cohort in Korea. </P><B>Methods</B><P> Prevalent patients with PD were selected from the CRC registry for ESRD, a prospective cohort study on dialysis patients in Korea. Patients were categorized into four groups by quartiles of BMI. Cox regression analysis was used to calculate the adjusted hazard ratio (HR) of mortality with a BMI of quartile 2 (21.4 - 23.5 kg/m<SUP>2</SUP>) as the reference. </P><B>Results</B><P> A total of 900 prevalent patients undergoing PD were included. The median follow-up period was 24 months. The multivariate Cox proportional hazard model showed that the lowest quartile of BMI was associated with higher mortality (HR 3.00,95% confidence interval (CI), 1.26 - 7.15). However, the higher quartiles of BMI were not associated with mortality compared with the reference category of BMI quartile 2 (Quartile 3: HR 1.11, 95% CI, 0.43 - 2.85, Quartile 4: H R 1.64,95% CI, 0.66 - 4.06) after adjustment for clinical variables. </P><B>Conclusions</B><P> Lower BMI was a significant risk factor for death, but increased BMI was not associated with mortality in Korean PD patients. </P>
Multiple cardiac metastases from a nonfunctioning pancreatic endocrine tumor
( Yong Hyeok Choi ),( Hye Suk Han ),( Sung Nam Lim ),( Sang Yeub Lee ),( Ji Hae Koo ),( Ok Jun Lee ),( Ki Hyeong Lee ),( Seung Taik Kim ) 대한내과학회 2011 대한내과학회 추계학술발표논문집 Vol.2011 No.1
Introduction: Pancreatic endocrine tumors (PETs) are uncommon neoplasm and the most common metastatic site is liver. However, intrathoracic metastasis of PET is very rare. The authors report a case of nonfunctioning PET with multiple cardiac metastases. Case report: A 56-year-old man presented with progressively worsening palpable abdominal mass. Computed tomography (CT) scan of abdomen revealed relatively well marginated inhomogeneous low attenuation masses in the head and tail of pancreas. CT scan of chest and transthoracic echocardiography showed multiple, enhancing masses in left pericardium. A needle biopsy was performed on the masses in the tail of pancreas and left ventricular apical pericardium; histologic examination revealed PET by morphology on H&E and by immunohistochemical staining which was positive for synaptophysin, chromogranin, and CD 56. Conclusion: This is the first report of PET with multiple cardiac metastases of previously undescribed metastatic sites. Although it is very rare, PET has the potential to metastasize to heart or pericardium, and for patients with PETs who present with new cardiac symptoms or signs, the clinician should be alert for the possibility of cardiac metastases.
( Yong Geun Jeong ),( Hyun Ok Kim ),( Hye Song Lim ),( Young Sool Hah ),( Hee Young Cho ),( Jia Hua Yu ),( Byung Hyun Park ),( Gou Young Koh ),( Sang Il Lee ) 대한류마티스학회 2012 대한류마티스학회지 Vol.19 No.2
Objective. Angiopoietin-1 (Ang1) is a potent angiogenic factor that can increase synovial angiogenesis and also enhance osteoblast maturation and bone formation. However, its role in rheumatoid arthritis (RA) has not been well documented. Thus, we investigated roles of Ang1 in collagen- induced arthritis (CIA). Methods. A recombinant adenovirus carrying the gene that encodes either cartilage oligomeric matrix protein (AdCOMP)-Ang1 (a modified form of Ang1) or LacZ (AdLacZ) was injected intravenously into CIA mice. Clinical, radiological, histopathological, and immunofluorescent analyses were performed. Serum levels of receptor activators of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) and expression of osteoblast maturation genes were analyzed. Results. AdCOMP-Ang1-injected mice developed more severe inflammation than the AdLacZ-injected mice. However, there were no significant differences in cartilage damage and bone erosion. More PECAM-1-positive blood vessels were seen in the synovium of the AdCOMP-Ang1-injected mice than in those injected with AdLacZ. Interestingly, a lower number of TRAP-positive osteoclasts were observed in AdCOMP-Ang1-injected CIA mice than in the AdLacZ group when comparing sections obtained from joints showing similar synovial proliferation. The serum OPG/RANKL ratio and expression of osteoblast maturation genes, such as runt-related transcription factor 2, bone sialoprotein, type 1 collagen, osteopontin, and osterix, were significantly upregulated in the AdCOMP-Ang1 group. Conclusion. COMP-Ang1 facilitates arthritis onset and increases synovial inflammation, but enhances osteoblast maturation, which in turn inhibits osteoclastogenesis by increasing the OPG/RANKL ratio in CIA. Our results suggest that careful investigation is necessary to delineate the possible therapeutic use of COMP-Ang1 as an adjunctive agent, in combination with anti-inflammatory therapies, for the prevention of bone destruction in RA.
Kim, Hyung-Sun,Kim, Sang-Ok,Kim, Yong-Tae,Jung, Ji-Kwon,Na, Byung-Ki,Lee, Joong-Kee Korean Chemical Society 2012 Bulletin of the Korean Chemical Society Vol.33 No.1
Novel type $Li_{1.1}V_{0.9-2x}W_xMo_xO_2$ powders were prepared by a solid-state reaction of $Li_2CO_3$, $V_2O_3$, $WO_2$ and $MoO_2$ precursors in a nitrogen atmosphere containing 10 mol % hydrogen gas, and assessed as anode materials in lithium-ion batteries. The specific charge and discharge capacities of the $Li_{1.1}V_{0.9-2x}W_xMo_xO_2$ anodes were higher than those of the bare $Li_{1.1}V_{0.9}O_2$ anode. The cyclic efficiency of these anodes was approximately 73.3% at the first cycle, regardless of the presence of W and Mo doping. The composite anode, which was composed of $Li_{1.1}V_{0.75}W_{0.075}Mo_{0.075}O_2$ (20 wt %) and natural graphite (80 wt %), demonstrated reasonable specific capacity, high cyclic efficiency, and good cycling performance, even at high rates without capacity fading.